Land: Kanada
Språk: engelska
Källa: Health Canada
PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE)
PHARMEL INC
A10BG03
PIOGLITAZONE
15MG
TABLET
PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) 15MG
ORAL
100
Prescription
THIAZOLIDINEDIONES
Active ingredient group (AIG) number: 0141541001; AHFS:
CANCELLED POST MARKET
2009-08-28
PRODUCT MONOGRAPH PR PHL-PIOGLITAZONE (Pioglitazone Hydrochloride) 15 mg, 30 mg, 45 mg Tablets Anti-Diabetic Agent PHARMEL INC. 6111 Royalmount Ave., Suite 100 Montreal, Quebec H4P 2T4 Date of Revision: January 9, 2013 Submission Control No: 161131 _ _ _phl-PIOGLITAZONE Product Monograph _ _Page 2 of 42_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .................................... 3 SUMMARY PRODUCT INFORMATION ................................................................................3 INDICATIONS AND CLINICAL USE .......................................................................................3 CONTRAINDICATIONS .............................................................................................................3 WARNINGS AND PRECAUTIONS ...........................................................................................4 ADVERSE REACTIONS .............................................................................................................8 DRUG INTERACTIONS ............................................................................................................11 DOSAGE AND ADMINISTRATION .......................................................................................13 OVERDOSAGE ...........................................................................................................................14 ACTION AND CLINICAL PHARMACOLOGY ....................................................................14 STORAGE AND STABILITY ...................................................................................................19 DOSAGE FORMS, COMPOSITION AND PACKAGING ....................................................19 PART II: SCIENTIFIC INFORMATION............................................................ 21 PHARMACEUTICAL INFORMATION .................................................................................21 CLINICAL TRIALS .................................................................................................................. Läs hela dokumentet